Literature DB >> 1415174

Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate.

G Castaman1, A Tosetto, F Rodeghiero.   

Abstract

A patient with benign monoclonal IgG lambda paraproteinemia, acquired von Willebrand syndrome (AVWS), and chronic melena successfully responding to high-dose intravenous immunoglobulin (lvlg) is reported. Coagulation parameters at admission were APTT (ratio) 1.68; VIII:C 11 IU/dL; vWF:Ag 7 IU/dL:Ricof less than 3 IU/dl. RIPA was greater than 1.8 mg/ml, and bleeding time (BT) was prolonged (18 min). No evidence for an in vitro inhibitor against the VIII/vWF complex was observed. VIII/vWF measurements showed a short-lived increase after both DDAVP and Hemate P, and BT was transiently normalized. After intravenous Ig (1 g/kg for 2 days), VIII/vWF measurements, hemostatic parameters and multimeric pattern were completely corrected (VIII/C 106 IU/dl, vWF:Ag 168 IU/dl, RiCof 147 IU/dl, APTT ratio 0.89, BT 5'), with a return to pre-infusion values after 15 days. Hemoccult test became negative and packed red cell transfusions, of which 130 units were administered during the last year, were no longer required. After 18 months the patient is on maintenance treatment with repeated courses of Ig, at 3 to 4-week intervals based on VIII/vWF and BT monitoring.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415174     DOI: 10.1002/ajh.2830410212

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Acquired von Willebrand syndrome in a 10-year-old girl with acute lymphoblastic leukaemia.

Authors:  Isabel Dorn; Ulrich Budde; Michael C Frühwald; Monika Pöppelmann; Ulrike Nowak-Göttl
Journal:  BMJ Case Rep       Date:  2009-06-21

Review 2.  Current management of von Willebrand's disease.

Authors:  G Castaman; F Rodeghiero
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 3.  High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease.

Authors:  P J Van Genderen; D N Papatsonis; J J Michiels; J J Wielenga; J Stibbe; F J Huikeshoven
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

4.  Acquired von Willebrand's disease.

Authors:  B J Hennessy; B White; M Byrne; O P Smith
Journal:  Ir J Med Sci       Date:  1998 Apr-Jun       Impact factor: 1.568

Review 5.  von Willebrand factor regulation of blood vessel formation.

Authors:  Anna M Randi; Koval E Smith; Giancarlo Castaman
Journal:  Blood       Date:  2018-06-04       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.